Frontage Holdings Corporation (HKG:1521)
Hong Kong · Delayed Price · Currency is HKD 1.080
0.00 (0.00%)
Feb 13, 2026, 3:11 PM HKT
Frontage Holdings Market Cap
Frontage Holdings has a market cap or net worth of 2.19 billion as of February 13, 2026. Its market cap has decreased by -36.34% in one year.
Market Cap
2.19B
Enterprise Value
3.02B
Revenue
1.99B
Ranking
n/a
PE Ratio
72.68
Stock Price
1.08
Market Cap Chart
Since May 30, 2019, Frontage Holdings's market cap has decreased from 6.73B to 2.19B, a decrease of -67.44%. That is a compound annual growth rate of -15.39%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 12, 2026 | 2.19B | 8.00% |
| Dec 31, 2025 | 2.03B | -43.71% |
| Dec 31, 2024 | 3.60B | -23.57% |
| Dec 29, 2023 | 4.71B | -20.20% |
| Dec 30, 2022 | 5.91B | -27.11% |
| Dec 31, 2021 | 8.10B | -6.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| May 30, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Jiangsu Recbio Technology | 3.05B |
| Clover Biopharmaceuticals | 2.86B |
| SinoMab BioScience | 2.48B |
| Antengene Corporation | 2.36B |
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 2.32B |
| Mabpharm | 2.10B |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 1.98B |
| Zhaoke Ophthalmology | 1.90B |